Company Launch Massalia Therapeutics launches to advance novel therapies for patients with complex conditions intersecting oncology and fibrosis
Company Launch Duhn Therapeutics, launched by Landmark BioVentures, signs global license agreement with OM Pharma to further advance clinical-stage, lipid-based cancer immunotherapy
Company Launch SPIMA Therapeutics Launches to Transform Peptide-Based Immunotherapies and Announces Global Licensing Agreement with SATT AxLR